Currently, several pharmacological agents targeting the PI3K/Akt/mTOR axis are under investigation in clinical trials aimed at combining these agents with standard therapies to overcome acquired resistance across various cancer types [231, 236]. This evidence concerns the gene PIK3CA and cancer.